{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-062337","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.774350+00:00","generated_at":"2026-05-18T08:54:04.700358+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Longeveron receives FDA clearance for Phase 2 trial of laromestrocel in pediatric dilated cardiomyopathy","bullets":["FDA approved IND for a Phase 2 pivotal registration study of laromestrocel for pediatric DCM.","Trial initiation anticipated in first half of 2026.","Nearly 40% of children with DCM require heart transplant or die within 2 years of diagnosis.","Allogeneic mesenchymal stem cell therapy may address anti-inflammatory and pro-vascular mechanisms."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-062337","json":"https://secwatch.observer/filing/0001213900-25-062337.json","markdown":"https://secwatch.observer/filing/0001213900-25-062337.md","text":"https://secwatch.observer/filing/0001213900-25-062337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025062337/0001213900-25-062337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025062337/ea0248389-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:54:04.700358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}